XNews

Claude Discovers Novel ART Enzyme System in Phages

Claude, Anthropic's AI, discovered a novel enzyme system named ART in phage DNA, featuring a reverse transcriptase and repetitive DNA array similar to CRISPR. The discovery was made by 950 Claude agents analyzing over 200,000 reverse transcriptases in 21 hours, and was experimentally validated by Anthropic's life sciences team.

Key insights

Discovery Process by Claude Agents

Anthropic announced that Claude autonomously discovered a new enzyme system in phage DNA. Researchers gave a single initial prompt to search for interesting reverse transcriptases. Approximately 950 Claude agents ran for 21 hours, consuming 210 million tokens. They screened over 200,000 reverse transcriptases, narrowed to 3,500 candidates, and selected 20 for human review. One agent recognized the repetitive array directly from raw sequence data, counted repeats, measured spacing, compared with known systems, and confirmed it was novel before submitting to humans.

Structure of the ART System

The newly discovered system, named ART (Array-associated Reverse Transcriptase), consists of three components: a reverse transcriptase enzyme, a partner gene of unknown function, and a long array of evenly spaced repetitive DNA sequences. This structure resembles CRISPR, which also has repetitive arrays that store guide information. Experiments confirmed that the ART array is transcribed into a set of distinct short RNAs, suggesting a potentially programmable mechanism similar to CRISPR.

Potential as a Gene Editing Tool

The ART system shares key features with CRISPR and other known systems that can cut, copy, or paste DNA. Only a few such systems have been found previously, and all have been developed into biotechnological tools. CRISPR has already led to gene editing drugs, and others are being developed. However, Anthropic acknowledges that the precise function of ART is not yet known. CRISPR pioneer Feng Zhang reviewed the preprint and called it a good example of AI agents participating in biological discovery.

Experimental Validation by Anthropic

Anthropic's life sciences team, formed in spring 2026, built a wet lab in the Bay Area for BSL-1 and BSL-2 level research. All experiments were conducted by human scientists. The team used publicly available Claude Science and Claude Code tools. They verified the discovery by performing experiments proposed by Claude. Anthropic is now seeking external research collaborations and inviting scientists to propose joint projects.

AI's Role in Accelerating Biological Discovery

Anthropic CEO Dario Amodei highlighted that AI performance in intellectual domains has rapidly progressed from weak to superhuman in a few years. He noted that while biology requires experimentation, AI can collaborate with humans to perform experiments and iterate on findings. He believes AI could eventually control lab equipment safely. The goal is to accelerate the first stage of fundamental biological discoveries, potentially increasing the number of candidates in the drug development pipeline.

Future Implications and Collaboration Opportunities

Anthropic is investing in life sciences to accelerate public benefits of AI. They aim to grow their life sciences team and work with other scientists. The discovery process used publicly available tools, meaning other labs can replicate the AI-driven hypothesis generation and human verification workflow. Anthropic is accepting research collaboration proposals and recruiting for their life sciences team.

Source posts